Arginine-Rich Ionic Complementary Peptides as Potential Drug Carriers: Impact of Peptide Sequence on Size, Shape and Cell Specificity

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 12, Issue 6, 2016, Pages 1479-1488

  Wan, Zizhen ^a   Lu, Sheng ^a   Zhao, Danyang ^a   Ding, Yong ^a   Chen, P ^a  

^a UNIVERSITY OF WATERLOO   (Canada)

Author keywords

Cell specificity; Drug delivery; Nanotechnology; Peptide

Indexed keywords

AMINO ACIDS; CELLS; CYTOLOGY; DISEASES; DRUG DELIVERY; IONIC DRUGS; NANOTECHNOLOGY;

ANTICANCER DRUG; IONIC-COMPLEMENTARY PEPTIDE; LUNG CANCER CELLS; MCF-7 BREAST CANCER CELLS; NANOSTRUCTURE FORMATION; PEPTIDE COMPLEX; PEPTIDE SEQUENCES; SELF-ASSEMBLING PEPTIDES;

PEPTIDES;

ARGININE; EAR16 II; EAR8 II; EAR8 IIA; ELLIPTICINE; ELR8 IIA; NANOCARRIER; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; DRUG CARRIER; OLIGOPEPTIDE; PEPTIDE;

A549 CELL LINE; AMINO ACID SEQUENCE; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; ATOMIC FORCE MICROSCOPY; BLOOD COMPATIBILITY; CANCER INHIBITION; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG FORMULATION; HEMOLYSIS; HUMAN; HUMAN CELL; HYDROPHILICITY; IC50; MCF 7 CELL LINE; NONHUMAN; PEPTIDE ANALYSIS; PROTEIN CONFORMATION; PROTEIN SECONDARY STRUCTURE; RABBIT; SURFACE TENSION; TRANSMISSION ELECTRON MICROSCOPY; CHEMISTRY;

AMINO ACID SEQUENCE; ARGININE; DRUG CARRIERS; HUMANS; OLIGOPEPTIDES; PEPTIDES;

EID: 84964944703     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2016.01.008     Document Type: Article

References (42)

1. Venturoli D., Rippe B. Ficoll and dextran vs. globular proteins as probes for testing glomerular permselectivity: effects of molecular size, shape, charge, and deformability. Am J Physiol Renal Physiol 2005, 288:F605-F613.
2. Davis M.E., Chen Z.G., Shin D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008, 7:771-782.
3. Petros R.A., DeSimone J.M. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov 2010, 9:615-627.
4. Gratton S.E., Ropp P.A., Pohlhaus P.D., Luft J.C., Madden V.J., Napier M.E., et al. The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci U S A 2008, 105:11613-11618.
5. Geng Y., Dalhaimer P., Cai S., Tsai R., Tewari M., Minko T., et al. Shape effects of filaments versus spherical particles in flow and drug delivery. Nat Nanotechnol 2007, 2:249-255.
6. Drummond D.C., Meyer O., Hong K., Kirpotin D.B., Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 1999, 51:691-743.
7. Moyer T.J., Finbloom J.A., Chen F., Toft D.J., Cryns V.L., Stupp S.I. pH and amphiphilic structure direct supramolecular behavior in biofunctional assemblies. J Am Chem Soc 2014, 136:14746-14752.
8. Christian D.A., Cai S., Garbuzenko O.B., Harada T., Zajac A.L., Minko T., et al. Flexible filaments for in vivo imaging and delivery: persistent circulation of filomicelles opens the dosage window for sustained tumor shrinkage. Mol Pharm 2009, 6:1343-1352.
9. Bellomo E.G., Wyrsta M.D., Pakstis L., Pochan D.J., Deming T.J. Stimuli-responsive polypeptide vesicles by conformation-specific assembly. Nat Mater 2004, 3:244-248.
10. Shao H., Parquette J.R. Controllable peptide-dendron self-assembly: interconversion of nanotubes and fibrillar nanostructures. Angew Chem 2009, 48:2525-2528.
11. Langer R. Drug delivery and targeting. Nature 1998, 392:5-10.
12. Allen T.M. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002, 2:750-763.
13. Lindsay M.A. Peptide-mediated cell delivery: application in protein target validation. Curr Opin Pharmacol 2002, 2:587-594.
14. Aina O.H., Sroka T.C., Chen M.L., Lam K.S. Therapeutic cancer targeting peptides. Biopolymers 2002, 66:184-199.
15. Temsamani J., Vidal P. The use of cell-penetrating peptides for drug delivery. Drug Discov Today 2004, 9:1012-1019.
16. Zhang X.X., Eden H.S., Chen X. Peptides in cancer nanomedicine: drug carriers, targeting ligands and protease substrates. J Control Release 2012, 159:2-13.
17. Zhu L., Wang T., Perche F., Taigind A., Torchilin V.P. Enhanced anticancer activity of nanopreparation containing an MMP2-sensitive PEG-drug conjugate and cell-penetrating moiety. Proc Natl Acad Sci U S A 2013, 110:17047-17052.
18. Lim Y.B., Lee E., Lee M. Cell-penetrating-peptide-coated nanoribbons for intracellular nanocarriers. Angew Chem 2007, 46:3475-3478.
19. Andrew MacKay J., Chen M., McDaniel J.R., Liu W., Simnick A.J., Chilkoti A. Self-assembling chimeric polypeptide-doxorubicin conjugate nanoparticles that abolish tumours after a single injection. Nat Mater 2009, 8:993-999.
20. Lu S., Bennett W.F.D., Ding Y., Zhang L., Fan H.Y., Zhao D., et al. Design and Characterization of a Multifunctional pH-Triggered Peptide C8 for Selective Anticancer Activity. Adv Healthc Mater 2015, 4:2709-2718.
21. Fung S.Y., Yang H., Bhola P.T., Sadatmousavi P., Muzar E., Liu M., et al. Self-Assembling Peptide as a Potential Carrier for Hydrophobic Anticancer Drug Ellipticine: Complexation, Release and In Vitro Delivery. Adv Funct Mater 2009, 19:74-83.
22. Fung S.Y., Yang H., Chen P. Sequence Effect of Self-Assembling Peptides on the Complexation and In Vitro Delivery of the Hydrophobic Anticancer Drug Ellipticine. PLoS ONE 2008, 3:e1956.
23. Zhang S., Holmes T., Lockshin C., Rich A. Spontaneous assembly of a self-complementary oligopeptide to form a stable macroscopic membrane. Proc Natl Acad Sci U S A 1993, 90:3334-3338.
24. Lu S., Wang H., Sheng Y.B., Liu M.Y., Chen P. Molecular binding of self-assembling peptide EAK16-II with anticancer agent EPT and its implication in cancer cell inhibition. J Control Release 2012, 160:33-40.
25. Bawa R., Fung S.-Y., Shiozaki A., Yang H., Zheng G., Keshavjee S., et al. Self-assembling peptide-based nanoparticles enhance cellular delivery of the hydrophobic anticancer drug ellipticine through caveolae-dependent endocytosis. Nanomedicine 2012, 8:647-654.
26. Wu Y., Sadatmousavi P., Wang R., Lu S., Yuan Y.F., Chen P. Self-assembling peptide-based nanoparticles enhance anticancer effect of ellipticine in vitro and in vivo. Int J Nanomed 2012, 7:3221-3233.
27. Ma W., Lu S., Pan P., Sadatmousavi P., Yuan Y., Chen P. Pharmacokinetics of peptide mediated delivery of anticancer drug ellipticine. PLoS ONE 2012, 7:e43684.
28. Mrabet N.T., Vandenbroeck A., Vandenbrande I., Stanssens P., Laroche Y., Lambeir A.M., et al. Arginine Residues as Stabilizing Elements in Proteins. Biochemistry 1992, 31:2239-2253.
29. Borders C.L., Broadwater J.A., Bekeny P.A., Salmon J.E., Lee A.S., Eldridge A.M., et al. A Structural Role for Arginine in Proteins-Multiple Hydrogen-Bonds to Backbone Carbonyl Oxygens. Protein Sci 1994, 3:541-548.
30. Rothbard J.B., Jessop T.C., Lewis R.S., Murray B.A., Wender P.A. Role of Membrane Potential and Hydrogen Bonding in the Mechanism of Translocation of Guanidinium-Rich Peptides into Cells. J Am Chem Soc 2004, 126:9506-9507.
31. Mishra A., Lai G.H., Schmidt N.W., Sun V.Z., Rodriguez A.R., Tong R., et al. Translocation of HIV TAT peptide and analogues induced by multiplexed membrane and cytoskeletal interactions. Proc Natl Acad Sci U S A 2011, 108:16883-16888.
32. Fung S.Y., Yang H., Sadatmousavi P., Sheng Y., Mamo T., Nazarian R., et al. Amino Acid Pairing for De Novo Design of Self-Assembling Peptides and Their Drug Delivery Potential. Adv Funct Mater 2011, 21:2456-2464.
33. Fung S.Y., Yang H., Chen P. Sequence effect of self-assembling peptides on the complexation and in vitro delivery of the hydrophobic anticancer drug ellipticine. PLoS ONE 2008, 3:e1956.
34. Ringstad L., Schmidtchen A., Malmsten M. Effect of Peptide Length on the Interaction between Consensus Peptides and DOPC/DOPA Bilayers. Langmuir 2006, 22:5042-5050.
35. Fung S.Y., Duhamel J., Chen P. Solvent effect on the photophysical properties of the anticancer agent ellipticine. J Phys Chem A 2006, 110:11446-11454.
36. Koga T., Matsuoka M., Higashi N. Structural control of self-assembled nanofibers by artificial beta-sheet peptides composed of D- or L-isomer. J Am Chem Soc 2005, 127:17596-17597.
37. Bai S.M., Zhang X.L., Lu Q., Sheng W.Q., Liu L.J., Dong B.J., et al. Reversible Hydrogel-Solution System of Silk with High Beta-Sheet Content. Biomacromolecules 2014, 15:3044-3051.
38. Chen C., Cheng Y.C., Yu C.H., Chan S.W., Cheung M.K., Yu P.H.F. In vitro cytotoxicity, hemolysis assay, and biodegradation behavior of biodegradable poly(3-hydroxybutyrate)-poly(ethylene glycol)-poly(3-hydroxybutyrate) nanoparticles as potential drug carriers. J Biomed Mater Res A 2008, 87A:290-298.
39. Fung S.Y., Keyes C., Duhamel J., Chen P. Concentration effect on the aggregation of a self-assembling oligopeptide. Biophys J 2003, 85:537-548.
40. Owens D.E., Peppas N.A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 2006, 307:93-102.
41. Howard M.D., Jay M., Dziublal T.D., Lu X.L. PEGylation of nanocarrier drug delivery systems: State of the art. J Biomed Nanotechnol 2008, 4:133-148.
42. Mo R., Jiang T.Y., DiSanto R., Tai W.Y., Gu Z. ATP-triggered anticancer drug delivery. Nat Commun 2014, 5:3364.